Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045122 | 0.89 | NPC1 (0.39) | NPC1GALR3NR2F2RAB9AAPP | |
| SCHEMBL31045255 | 0.87 | TSHR (0.41) | TSHRHSD17B10ABCG2NPC1GALR3 | |
| SCHEMBL31045112 | 0.86 | TSHR (0.38) | TSHRHSD17B10ABCG2NPC1GALR3 | |
| SCHEMBL31044961 | 0.85 | SLC6A3 (0.41) | TSHRHSD17B10NPC1GALR3NR2F2 | |
| SCHEMBL31045066 | 0.83 | NPC1 (0.35) | NPC1GALR3NR2F2RAB9AAPP | |
| SCHEMBL31044730 | 0.83 | NPC1 (0.39) | NPC1GALR3NR2F2RAB9AAPP | |
| SCHEMBL31045039 | 0.83 | APP (0.51) | APPPDE5AESR1 | |
| SCHEMBL31045084 | 0.82 | KCNH2 (0.40) | NPC1GALR3NR2F2RAB9AAPP | |
| SCHEMBL31045209 | 0.82 | HRH4 (0.41) | TSHRHSD17B10NPC1GALR3NR2F2 | |
| SCHEMBL31044756 | 0.82 | USP1 (0.37) | ABCG2NPC1GALR3NR2F2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | G6PD, SDHA, NQO1 | TSHR 2815/4885HSD17B10 1017/4885ABCG2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.